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Abstract
Background: Intraocular medulloepithelioma is commonly treated with primary enucleation. Conservative
treatment options include brachytherapy, local resection and/or cryotherapy in selected cases. We report for the
first time the use of targeted chemotherapy to treat a ciliary body medulloepithelioma with aqueous and vitreous
seeding.
Case presentation: A 17-month-old boy with a diagnosis of ciliary body medulloepithelioma with concomitant
seeding and neovascular glaucoma in the right eye was seen for a second opinion after parental refusal of
enucleation. Examination under anesthesia showed multiple free-floating cysts in the pupillary area associated with
iris neovascularization and a subluxated and notched lens. Ultrasound biomicroscopy revealed a partially cystic
mass adjacent to the ciliary body between the 5 and 9 o’clock meridians as well as multiple nodules in the
posterior chamber invading the anterior vitreous inferiorly. Fluorescein angiography demonstrated peripheral retinal
ischemia. Left eye was unremarkable. Diagnosis of intraocular medulloepithelioma with no extraocular invasion was
confirmed and conservative treatment initiated with combined intracameral and intravitreal melphalan injections
given according to the previously described safety-enhanced technique. Ciliary tumor and seeding totally regressed
after a total of 3 combined intracameral (total dose 8.1 μg) and intravitreal (total dose 70 μg) melphalan injections
given every 7–10 days. Ischemic retina was treated with cryoablation as necessary. Three years later, ab interno
trabeculotomy followed by 360° gonioscopy-assisted transluminal trabeculotomy 6months later was performed for
uncontrolled intraocular pressure despite antihypertensive drugs combined to cyclophotocoagulation and 7
intravitreal anti-VEGF injections for recurrent iris neovascularization. Cataract was removed at the same operative
time. The child has remained disease- and metastasis-free at a 5-year follow-up since the last melphalan injection
(25-month follow-up after the combined lensectomy-trabeculotomy) with a controlled intraocular pressure under
topical quadritherapy and a best corrected Snellen visual acuity of 0.08.
Conclusions: We report for the first time complete regression of a non-infiltrating ciliary body medulloepithelioma
with seeding achieved with only a small number of intracameral and intravitreal melphalan injections. Concomitant
secondary neovascular glaucoma and cataract needed appropriate management to allow long-term eye and vision
preservation.
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Background
Intraocular medulloepithelioma is a rare, nonhereditary,
neuroepithelial tumor, usually arising from the nonpig-
mented ciliary epithelium of the ciliary body, more rarely
the optic nerve, the retina or the iris [1]. Its exact inci-
dence is not known. Almost all cases are unilateral, with
no gender or racial predilection. Diagnosis is made
within the first decade of life in about 80% of the cases
[2]. Most patients present with loss of vision, pain, leu-
kocoria or a mass appearing in the anterior chamber [1,
3]. In 5% of the cases, a systemic association with pleur-
opulmonary blastoma caused by heterozygous DICER1
mutations has been found [1]. Histopathologically, intra-
ocular medulloepithelioma can be classified into nonter-
atoid and teratoid types and both can be benign or
malignant. Even in the malignant form, these slowly
growing tumors do not tend, however, to metastatize,
unless extraocular extension occurs [1–3].
Characteristic features of ciliary body medulloepithe-
lioma include a grey-white to fleshy pink mass with a
various quantity of cysts adjacent to the ciliary body, a
lens notching with or without subluxation and a neo-
plastic cyclitic membrane [3, 4]. The cysts within the
mass may break away and float freely into the aqueous
or the vitreous cavity. Coexistence of persistent hyper-
plastic primary vitreous has been reported in 20% of the
cases [3, 4]. Around 50% of the cases are complicated
with glaucoma and/or cataract [1–3]. Treatment options
include enucleation [1–4], plaque brachytherapy [1, 2,
5], surgical resection [2, 4, 6] and cryotherapy [2, 4].
Here we report for the first time a case of intraocular
medulloepithelioma with seeding at presentation suc-
cessfully treated with intracameral and intravitreal mel-
phalan chemotherapy.
Case presentation
A previously healthy 17-month-old boy was given topical
antibiotics for a right eye redness appearing in the con-
text of an ear, nose and throat infection. One week later,
fixed mydriasis of the same eye was observed, and the
child seen elsewhere for evaluation (Fig. 1). Ophthalmo-
logic examination revealed an intraocular mass and the
child was referred to a specialized oncology centre for
further investigations. Diagnosis of intraocular medulloe-
pithelioma with anterior chamber seeding and neovascu-
lar glaucoma was made and immediate enucleation
advised. Parents refused the intervention and consulted
us for a second opinion. Examination under general
anesthesia showed multiple free-floating cysts in the
pupillary area of the right eye with iris neovasculariza-
tion and a notched lens that was subluxated superona-
sally (Fig. 2a). Intraocular pressure was controlled (17
mmHg) under topical beta-blocker and oral acetazol-
amide. Fundus examination was normal. Fluorescein
angiography revealed anterior segment leakage with in-
ferior peripheral retinal ischemia. Ultrasound biomicro-
scopy performed on the 12 meridians showed a
complete iridocorneal angle closure and an irregular-
surfaced, partially cystic mass adjacent to the ciliary
body between the 5 and 9 o’clock meridians. Multiple
nodules were invading the posterior chamber and anter-
ior vitreous invasion was also seen inferiorly (Fig. 2b).
Left eye examination was unremarkable. Clinical appear-
ance and ultrasonographic features confirmed the diag-
nosis of ciliary body medulloepithelioma. There being
no signs of extraocular extension nor ciliary infiltration,
conservative treatment was initiated. After obtaining
parents’ informed consent, combined intracameral
(2.25 μg/0.15 ml) and intravitreal melphalan (30 μg/0.15
ml) injections given according to a previously described
safety-enhanced technique to avoid potential extraocular
tumor spread [7, 8]. Injected doses were similar to the
ones used in the treatment of aqueous and vitreous
seeding in retinoblastoma. Cytopathological analysis of
the aqueous tap performed prior to injection showed
small aggregates of malignant cells with high nuclear
cytoplasmic ratio that were negative for synaptophysin
on immunocytochemistry (Fig. 2c). Partial regression of
both ciliary mass and seeding was observed 1 week later,
encouraging treatment to be repeated. In total, 3 com-
bined intracameral (total dose 8.1 μg) and intravitreal
(total dose 70 μg) melphalan injections were given every
7–10 days, resulting in complete response of the main
tumor (documented on UBM after 2 combined
Fig. 1 Mydriasis with sectorial inferotemporal leukocoria in the right eye of the 17-month-old child as presenting sign of intraocular
medulloepithelioma. Note the darker right eye appearance due to iris neovascularization and the inferior transillumination due to the subluxated
colobomatous lens
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injections) and aqueous/vitreous seeding (observed after 3
combined injections) (Fig. 2d-e). One week after the final
injections, dense anterior chamber hyphema related to
persistent iris neovascularization occurred. After careful
anterior chamber washout under melphalan perfusion
(15 μg/ml), iris neovascularization was managed with
cryoablation of the peripheral retinal ischemia and intra-
vitreal anti-vascular endothelial growth factor (anti-
VEGF). Three years later, the patient underwent ab
interno trabeculotomy followed by a 360° gonioscopy-
assisted transluminal trabeculotomy 6 months later to
manage uncontrolled intraocular pressure despite antihy-
pertensive drugs combined with cyclophotocoagulation
and 7 intravitreal anti-VEGF injections for recurrent iris
neovascularization. Cataract surgery with posterior capsu-
lorhexis, anterior vitrectomy and sulcus implantation of a
three-piece intraocular lens was performed during the first
glaucoma surgery. Cytopathologic analysis of the vitrec-
tomy fluid was negative for tumor cells. One year after the
cataract was removed, YAG-laser capsulotomy was per-
formed for posterior capsular lens opacification. The child
has remained disease and metastasis-free at a 5-year
follow-up since the last chemotherapy with a controlled
intraocular pressure under topical quadritherapy and a
best-corrected Snellen visual acuity of 0.08.
Discussion and conclusions
Intraocular medulloepithelioma is a rare tumor of un-
known incidence but still represents the most frequent
pediatric primary malignant intraocular tumor after ret-
inoblastoma [9]. Standards of care do not exist. Large
size or invasive medulloepitheliomas are commonly
treated with primary enucleation [3, 4, 10, 11]. Exenter-
ation in combination with irradiation and/or adjuvant
chemotherapy may be necessary in cases with orbital in-
volvement [3, 12]. Small or medium-size well-
circumscribed tumors can be treated conservatively with
I-125 or Ru-106 plaque radiotherapy [1, 2, 5]. Local re-
section with iridocyclectomy or partial lamellar sclerou-
vectomy are usually insufficient, displaying a high
recurrence rate requiring secondary enucleation [4, 6,
13]. To date, the role of first line chemotherapy for con-
servative management of medulloepithelioma is not
known, as its use has been restricted to adjuvant or neo-
adjuvant therapy of cases with orbital invasion and/or
metastasis [14–17].
In this report, we describe for the first time the con-
servative management of a non-infiltrating ciliary body
medulloepithelioma complicated with seeding at presen-
tation using intraocular melphalan injections. Presence
of seeding was so far considered as an indication for
Fig. 2 a. Anterior segment chamber photography of the right eye at diagnosis showing iris neovascularization, multiple free-floating cysts in the
pupillary area as well as a subluxated and notched lens. b. Ultrasound biomicroscopy (35 MHz) on the 6 o’clock meridian displaying an
iridocorneal angle closure and an irregular-surfaced mass with intratumoral cysts adjacent to the ciliary body, growing from the ciliary epithelium
into the posterior chamber without invading the ciliary muscle. Clumps of hyperechogenic material are found in the posterior chamber (cysts)
and the anterior vitreous (dust). c. Cytology analysis of the aqueous tap performed before treatment showing aggregates of malignant small cells
with high nuclear/cytoplasmic ratio and finely granular chromatin. d-e. Anterior segment photography and ultrasound biomicroscopy one month
after 3 intracameral and 3 intravitreal melphalan injections showing complete response of the primary tumor and the aqueous/vitreous seeding.
Iris neovascularization had transiently regressed after concomitant intravitreal anti-vascular endothelial factor and cryoablation of the peripheral
ischemic retina
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enucleation [4]. Melphalan is a well-known drug
employed in the treatment of various solid and
hematopoietic cancers such as ovarian cancer, breast
cancer or multiple myeloma [18]. Its cytotoxic activity is
mediated by its DNA alkylating properties, which leads
to cell death [18]. Melphalan injections directly into the
vitreous or the aqueous humor via intravitreal or intra-
cameral injections respectively, allow high intraocular
tumoricidal drug concentrations to be reached, while by-
passing systemic adverse effects and are therefore cur-
rently the treatment of choice for vitreous and aqueous
seeding in retinoblastoma [19, 20]. Recently intravitreal
melphalan has also been used to salvage two cases with
primary vitreoretinal lymphoma [21]. In our case, intra-
ocular melphalan alone was sufficient to achieve
complete regression, not only of the seeding but also of
the primary solid tumor, presumably because of its fri-
able nature and the absence of concomitant ciliary
muscle infiltration. Injected doses were decided based
on our experience with retinoblastoma. The minimal
tumoricidal drug concentration for intraocular medul-
loepithelioma remains to be established. Posterior capsu-
lar cataract needing surgery 3 years after treatment
completion was the only treatment-related adverse effect
observed in our patient.
In conclusion, we report herein for the first time a
case of non-invasive ciliary body medulloepithelioma
with seeding at presentation successfully treated with
only a small number of intraocular melphalan injections.
To our knowledge, this is the first case of intraocular
medulloepthelioma with seeding to be managed conser-
vatively. Concomitant secondary neovascular glaucoma
and cataract needed appropriate management to allow
long-term eye and vision preservation. Further studies
will help to better define the role of targeted chemother-
apy for intraocular medulloepithelioma in the future.
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